The product label for ezetimibe (Zetia, Merck/Schering-Plough) has been revised to include hypersensitivity reactions, including rash and angioedema, as part of the adverse reactions section, according to Schering-Plough. The companies submitted an updated product label to FDA in April based on post-marketing surveillance, and the new label entered the market in July.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Ezetimibe labeling updated to include additional safety information

Newsletter